scholarly journals Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

2013 ◽  
Vol 24 (11) ◽  
pp. 2892-2897 ◽  
Author(s):  
P.L. Zinzani ◽  
J.M. Vose ◽  
M.S. Czuczman ◽  
C.B. Reeder ◽  
C. Haioun ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Subset Analysis ◽  
Mantle Cell ◽  
Long Term Follow Up

scholarly journals First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

2019 ◽  
Vol 37 (12) ◽  
pp. 984-991 ◽  
Author(s):  
Ian W. Flinn ◽  
Richard van der Jagt ◽  
Brad Kahl ◽  
Peter Wood ◽  
Tim Hawkins ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Time To Event ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell ◽  
Duration Of Response ◽  
Long Term Follow Up

PURPOSE The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data. PATIENTS AND METHODS Patients were monitored for a minimum of 5 years after completion of study treatment for the time-to-event end points of progression-free survival (PFS), event-free survival, duration of response, and overall survival per investigator assessment. Data on the number of patients who received second-line anticancer treatment and the occurrence of other malignancies were also collected. RESULTS The medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment group and 55.8% in the R-CHOP/R-CVP group. The difference in PFS was considered significant with a hazard ratio of 0.61 (95% CI, 0.45 to 0.85; P = .0025). The hazard ratio for event-free survival and duration of response ( P = .0020 and .0134, respectively) also favored the BR regimen over R-CHOP/R-CVP. However, no significant difference in overall survival was observed. The overall safety profiles of BR, R-CHOP, and R-CVP were as expected; no new safety data were collected during long-term follow-up. A higher number of secondary malignancies was noted in the BR treatment group. CONCLUSION Overall, BR demonstrated better long-term disease control than R-CHOP/R-CVP and should be considered as a first-line treatment option for patients with indolent and mantle-cell lymphoma.

Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission

Cancer ◽  
2003 ◽  
Vol 98 (12) ◽  
pp. 2630-2635 ◽  
Author(s):  
Issa F. Khouri ◽  
Rima M. Saliba ◽  
Grace-Julia Okoroji ◽  
Sandra A. Acholonu ◽  
Richard E. Champlin
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Mantle Cell Lymphoma ◽  
Autologous Stem Cell Transplantation ◽  
Cell Lymphoma ◽  
Disease Remission ◽  
Mantle Cell ◽  
Long Term Follow Up

Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results

2014 ◽  
Vol 14 (2) ◽  
pp. 107-113 ◽  
Author(s):  
Jia Ruan ◽  
Stephanie A. Gregory ◽  
Paul Christos ◽  
Peter Martin ◽  
Richard R. Furman ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Initial Therapy ◽  
Mantle Cell ◽  
Long Term Follow Up

scholarly journals Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

2011 ◽  
Vol 52 (9) ◽  
pp. 1675-1680 ◽  
Author(s):  
Vaishalee P. Kenkre ◽  
Walter L. Long ◽  
Jens C. Eickhoff ◽  
Jules H. Blank ◽  
Thomas A. McFarland ◽  
...  
Keyword(s):  
Pilot Study ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Long Term Follow Up

Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

2019 ◽  
Vol 19 ◽  
pp. S316
Author(s):  
Michael Wang ◽  
Simon Rule ◽  
Pier Luigi Zinzani ◽  
Andre Goy ◽  
Oliver Casasnovas ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Long Term Follow Up

Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

2011 ◽  
pp. 1-6
Author(s):  
Vaishalee P. Kenkre ◽  
Walter L. Long ◽  
Jens C. Eickhoff ◽  
Jules H. Blank ◽  
Thomas A. Mcfarland ◽  
...  
Keyword(s):  
Pilot Study ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Leukemia ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 1458-1461 ◽  
Author(s):  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Christopher Fegan ◽  
Franck Morschhauser ◽  
Lingling Han ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document